PROphylaxis for paTiEnts at risk of COVID-19 infecTion (PROTECT-V)
DiscussionDespite the introduction of vaccination, there remains a need for pre-exposure prophylactic agents against SARS-CoV-2. Several patient groups are more vulnerable to COVID-19 disease by virtue of underlying health conditions, treatments received or suboptimal responses to vaccination.Trial registrationClinicalTrials.gov NCT04870333. EudraCT 2020-004144-28
Source: Trials - Category: Research Source Type: clinical trials
More News: Autoimmune Disease | Cancer & Oncology | Covid Vaccine | COVID-19 | Dialysis | Research | SARS | Transplants | Vaccines